Open

Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer

The purpose of this study is to investigate the effects of using durvalumab plus platinum doublet chemotherapy (carboplatin/abraxane or carboplatin/pemetrexed) with or without abequolixron (RGX-104) in patients with non-small cell lung cancer (NSCLC) before surgery.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

At visits, you may have a physical exam, eye exam, an ECG, blood and serum tests

Incentives

In-person visits:
Approximately 65

Total length of participation:
Approximately 63 days on treatment + 5 years of follow-up

Looking for Specific Volunteers

Able to participate:

You have stage II-IIIA confirmed squamous or non-squamous NSCLC
You agree to not donate blood while participating in study or for at least 90 days following last infusion or last dose of durvalumab
Your are able to swallow and retain oral medication
You have a baseline O2 saturation by pulse oximetry that is ≥ 90% both at rest and while walking, off supplemental oxygen
You have a body weight of > 40 kg (88 lbs)

Not eligible if:

You receive live attenuated vaccine (or any vaccines, except for COVID-19 vaccinations and boosters) within 30 days prior to the first dose of study drugs
You have known to have tested positive for human immunodeficiency virus (HIV) or active tuberculosis infection
You have a history of interstitial lung disease
You have a history of pancreatitis
You have a history of allogenic organ transplantation

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Jared Weiss
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

22-2739

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.